Financials data is unavailable for this security.
View more
Year on year Mirum Pharmaceuticals Inc grew revenues 54.74% from 336.89m to 521.31m while net income improved from a loss of 87.94m to a smaller loss of 23.36m.
| Gross margin | 80.77% |
|---|---|
| Net profit margin | -4.48% |
| Operating margin | -4.25% |
| Return on assets | -3.09% |
|---|---|
| Return on equity | -8.65% |
| Return on investment | -3.96% |
More ▼
Cash flow in USDView more
In 2025, Mirum Pharmaceuticals Inc increased its cash reserves by 33.75%, or 75.24m. The company earned 55.83m from its operations for a Cash Flow Margin of 10.71%. In addition the company generated 40.14m cash from financing while 23.95m was spent on investing.
| Cash flow per share | 0.017 |
|---|---|
| Price/Cash flow per share | 5,910.88 |
| Book value per share | 6.06 |
|---|---|
| Tangible book value per share | 1.04 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.67 |
|---|---|
| Quick ratio | 2.55 |
| Total debt/total equity | 0.9845 |
|---|---|
| Total debt/total capital | 0.4961 |
More ▼
